Since the targeted therapies using cemiplimab and pembrolizumab (PD-1 inhibitors approved by the FDA) or EGFR inhibitors have not been approved in Japan, various cytotoxic anticancer drugs are used to treat cSCC that cannot be radically resected. The gene discussed is EGFR; the disease is skin squamous cell carcinoma.